2011•PubMedRequires access

[Pharmacokinetics and bioavailability of Puerarin self-microemulsion in Beagle dogs].

Xiaoxin Chen, Su Yuan, Geng Li, You-Ya Liang, Xiu Zhou, Chengshi Xie, Chaofeng Long

Open publisher page 1 citations

Abstract

OBJECTIVE: To estabolish a quantitative analysis method for pharmacokinetics and bioavailability of Puerarin self-microemulsion in Beagle dogs. METHODS: A crossover design was use to detect the pharmacokinetic parameters of Puerarin self-microemulsion and suspension in Beagle dogs. The concentration of Puerarin in plasma was determined with HPLC, the pharmacokinetics parameters and bioavailability was calculated with DAS 2. 1. 1 programs. RESULTS: T(max) of Puerarin self-microemulsion and suspension were 3.0 h and 2.0 h, C(max) were 2.14 mg/L and 1.061 mg/L, AUC(0-24) were 10.642 mg h/L and 3 mg x h/L, respectively. The bioavailability of Puerarin self-microemulsion relative to Puerarin suspension were 354.73%. CONCLUSION: Puerarin self-microemulsion can significantly improve the bioavailability in Beagle dogs.

About this research paper

What this paper is about

OBJECTIVE: To estabolish a quantitative analysis method for pharmacokinetics and bioavailability of Puerarin self-microemulsion in Beagle dogs. METHODS: A crossover design was use to detect the pharmacokinetic parameters of Puerarin self-microemulsion and suspension in Beagle dogs. The concentration of Puerarin in plasma was determined with HPLC, the pharmacokinetics parameters and bioavailability was calculated with DAS 2. 1. 1 programs. RESULTS: T(max) of Puerarin self-microemulsion and suspension were 3.0 h and 2.0 h, C(max) were 2.14 mg/L and 1.061 mg/L, AUC(0-24) were 10.642 mg h/L and 3 mg x h/L, respectively. The bioavailability of Puerarin self-microemulsion relative to Puerarin suspension were 354.73%. CONCLUSION: Puerarin self-microemulsion can significantly improve the bioavailability in Beagle dogs.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To estabolish a quantitative analysis method for pharmacokinetics and bioavailability of Puerarin self-microemulsion in Beagle dogs. METHODS: A crossover design was use to detect the pharmacokinetic parameters of Puerarin self-microemulsion and suspension in Beagle dogs. The concentration of Puerarin in plasma was determined with HPLC, the pharmacokinetics parameters and bioavailability was calculated with DAS 2. 1. 1 programs. RESULTS: T(max) of Puerarin self-microemulsion and suspension were 3.0 h and 2.0 h, C(max) were 2.14 mg/L and 1.061 mg/L, AUC(0-24) were 10.642 mg h/L and 3 mg x h/L, respectively. The bioavailability of Puerarin self-microemulsion relative to Puerarin suspension were 354.73%. CONCLUSION: Puerarin self-microemulsion can significantly improve the bioavailability in Beagle dogs.

Key concepts: Puerarin, Beagle, Bioavailability, Pharmacokinetics, Microemulsion, Chromatography, Chemistry, Pharmacology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Pharmacokinetics and bioavailability of Puerarin self-microemulsion in Beagle dogs]. — Research Paper | ScholarLens